cyrilzakka/clinical-trials huggingface dataset:
Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients

The efficacy of low dose aspirin appears to be substantially lower in diabetic patients, compared to patients without diabetes.

We will perform an observational study where we follow up patients with uncontrolled type 2 Diabetes Mellitus and low response to aspirin (Aspirin Resistance), during a period of 6 months in the diabetic clinic. Our hypothesis is that glucose control will improve the response to aspirin in those patients.


Eligibility Criteria:
Inclusion Criteria

1. Type 2 DM.
2. Patients that take aspirin.
3. Antecubital forearm veins allowing technically good sampling for platelet studies.
4. Reduced Laboratory response to aspirin.
5. HbA1c \> 8 %
6. The physician decides that there is an indication for glucose control.

Exclusion Criteria:

1. Acute ischemic stroke, acute coronary syndrome, (myocardial infarction or unstable angina pectoris), or revascularization by PCI or by-pass surgery within the last 6 months.
2. Acute kidney disease or chronic kidney disease with creatinine clearance \<30.
3. Acute liver disease or chronic liver disease with severe liver impairment.
4. Need for treatment with anticoagulants, clopidogrel, NSAID's, or thiazolidinediones.
5. Thrombocytopenia (platelet count \<150 x 109/L)
Reducing Pain in Emergency Department by Using Veinous Blood Gas Instead of Arterious Blood Gas

Blood gases are widely used in emergency and resuscitation services and are the key examination for exploring acid-base balance disorders (using pH, PaCO2 and HCO3 ) and gas exchange disorders (using PaO2 and PaCO2). This examination can be taken from both venous and arterial sample and its analysis depends on the type of blood sample. Currently, several studies have already shown the existence of a good correlation of pH and bicarbonates level between a venous and arterial sample. Thus, when this examination is prescribed for the purpose of highlighting and analyzing an acid-base disorder, venous blood gas is theoretically as efficient as arterial blood gas.

Due to the lack of evidence of benefit for the patient or the health care team of a venous blood gas rather than an arterial blood gas in the absence of suspicion of hypoxemia, arterial blood gas is currently the standard of care for the analysis of acid-base disorders. Indeed, among the university hospitals affiliated to the Paris Diderot University, the emergency departments carry out in their vast majority (4 of 5 E.D.) arterial blood gases. Demonstration of the superiority of veinous sample over arterial sample regarding pain could substantially modify current practices.

The investigator's main hypothesis is that, in the absence of suspicion of hypoxemia (normal oxygen saturation measured by plethysmography), the realization of a venous blood gas for the evaluation of the acid-base balance in the context of emergencies is less painful for patients, simpler for the health care team and provides sufficient biochemical information for the doctor in comparison with an arterial blood gas.


Eligibility Criteria:
Inclusion Criteria:

* necessity of blood gas analysis
* age \> 18 yo
* SpO2\>95% without supplemental oxygen
* no altered level of consciousness: Glasgow Coma Scale=15

Exclusion Criteria:

* Patient under guardianship or curatorship
* confusional state or patient unable to understand the protocol
* no social security
The Influence of Probiotics on the Immunologic Response to Vaccinations in Infants

Background: It is well established that the presence of bacteria in the intestine has a profound influence on health. Probiotics, ("beneficial bacteria") have shown ameliorating effects on various infectious diseases. The influence of probiotics on several immune-mediated conditions has also been investigated, among them, atopic dermatitis ("Asthma of the skin"), and milk allergy.

The precise mechanism of action of probiotics is not fully understood. Several animal and human studies have shown the probiotic bacteria to influence the immune system. The aim of the present study is to evaluate whether supplementing the diet with oral probiotics affects the immune response of children following routine vaccination against 4 common childhood viral diseases: Mumps, Measles, Rubella and Varicella.

Objective(s) and Hypothesis(es):

Hypothesis: Administration of probiotics will increase the amount of antibodies produced following vaccination for Measles, Mumps, Rubella and Varicella, by over 15%.

Objectives:

* To determine whether administration of probiotics during infancy influences antibody levels following the routine childhood vaccinations.
* To determine whether administration of probiotics during infancy influences the rate of adverse effects following the routine childhood vaccinations.

Potential Impact: Vaccines, alongside with the discovery of Penicillin, have been cited as the great public health successes of the 20th century. However, even in countries with maximal childhood immunization coverage, the protective effect is not optimal. For example, only 70% to 90% of children immunized against chickenpox are actually protected against the disease. If we succeed in raising these numbers, even by a single percent, it will have a huge impact on society.


Eligibility Criteria:
Inclusion Criteria:

* Age: 9-11 months.
* Parent or guardian intending to follow the recommended immunization schedule in Israel.
* Parent or guardian possessing sufficient knowledge of the Hebrew language.

Exclusion Criteria:

* Infants suffering from any chronic diseases / conditions resulting in immune depression.
* Infants taking medications affecting the immune system.
* Infants with permanent invasive catheters.
* Infants born prematurely (prior to gestational week 35)
* Parent or guardian objecting to collection of blood sample at the end of study.
Septal Positioning of Ventricular Implanted Cardioverter Defibrillator (ICD) Leads

This clinical trial is a multi center, prospective, randomized, parallel study designed to compare septal to apical ICD lead placement.

The primary objective of this clinical investigation is to demonstrate that septal positioning of the right ventricular defibrillation lead is not inferior to the apical positioning in terms of safety and efficacy in a population of ICD recipients.

Eligibility Criteria:
Inclusion Criteria:

* Age \>=18 years
* Signed written informed consent
* Approved indication for implantation of ICD / CRT-D device

Exclusion Criteria:

* Preexisting transvenous RV pacemaker or ICD leads
* Pacemaker dependency without sufficient intrinsic rhythm (≤ 30min-1)
* Hypertrophic obstructive cardiomyopathy
* Presence of intra-aortic balloon pump
* Inotropic drug (not digitalis) necessary for hemodynamic support
* Inability to perform VF induction testing due to anticipated high risk
* Condition likely to limit cooperation
* Unable to give informed consent
* Pregnancy or planned pregnancy in the next 6 months
* Patients with planned cardiac surgery within the next 3 months following randomization
* Patient is currently participating in a clinical investigation that includes an active treatment arm.
* Acute myocardial infarction within the previous 4 weeks.
Effect of Bupivacaine Liposome Anterior Serratus Deep Block on Chronic Pain After Breast Cancer Surgery: a Randomized Controlled Study

This study aims to investigate the effect and influence of liposome bupivacaine anterior serrat plane block on postoperative chronic pain in breast cancer patients, evaluate the therapeutic effect of liposome bupivacaine in postoperative chronic pain, and provide a new method for patients with postoperative chronic pain.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients (aged ≥18 years) who are scheduled to undergo unilateral modified radical breast cancer surgery

Exclusion Criteria:

* 1. Patients with coagulation dysfunction 2. There are infected patients at the puncture site 3. For patients allergic to any trial drug 4. Patients who take painkillers within 48 hours before surgery 5. Severe cardiopulmonary insufficiency, such as EF\< 40%, FEVC \< 50% expected; Uncontrolled hypertension; 6. Refuse to perform nerve block puncture 7. Mental disorders, epilepsy history; 8. Unable to give informed consent or are participating in other clinical trials.
Ketamine-enhanced Prolonged Exposure Therapy in PTSD

The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo to reduce symptoms of Posttraumatic Stress Disorder (PTSD) among Veteran receiving Prolonged Exposure Therapy.

In this single site clinical trial, intended to evaluate the safety and efficacy of repeated doses of ketamine in conjunction with prolonged exposure (PE) therapy for PTSD. Veterans who meet criteria for PTSD and the additional inclusion and exclusion criteria will be randomized to one of two treatment arms (placebo plus PE vs ketamine plus PE). Participants receive the study drug via intravenous infusion once per week for 3-weeks.

Eligibility Criteria:
Inclusion Criteria:

* male or female Veterans between the ages of 18 and 75 years
* diagnosis of PTSD
* ability to provide written informed consent

Exclusion Criteria:

* females who are currently pregnant or breastfeeding
* current high risk for suicide
* history of moderate/severe head injury
* history of psychosis
* current episode of mania/hypomania
* severe substance and/or alcohol use disorder in the last 6 months
Intrarectal Misoprostol in Postpartum Haemorrhage

Postpartum haemorrhage (PPH) remains the major cause of maternal mortality in France. The most efficient treatment of severe PPH is sulprostone which is associated with cardiac complications. The objective of this study was to assess the efficacy and the safety of intrarectal misoprostol for curative postpartum haemorrhage treatment.

We conducted a multicenter double blind randomized placebo control trial between June 2004 and December 2007, among consenting women with postpartum haemorrhage and failure to oxytocin treatment.

Our main criteria of judgement was quantification of blood loss and the use of sulprostone between the two groups using either misoprostol intrarectal tablets (5X200mg ) or placebo in similar opaque introducer.


Eligibility Criteria:
Inclusion Criteria:

* Older than 18 yrs old
* Giving birth after 32 Weeks of amenorrhea
* Post-partum haemorrhage due to atony
* Inefficiency off the first line treatment
* Written signed consent form

Exclusion Criteria:

* known allergy to prostaglandin
* haemostasis anomalies before labour
* anticoagulant treatment
* fetal death
* accreta or percreta placenta
* under 18 years
* delivery before 32 weeks of amenorrhea
* post-partum bleeding not suspected to be due to atonic uterus
The Effect of Transtheoretical Model-based Motivational Interview on Self-efficacy and Illness Compliance

Aim: This study was planned to determine the effect of transtheoretical model-based motivational interviewing on patients\&#39; self-efficacy and disease adherence in patients receiving haemodialysis treatment.

Study design and methods: This study was conducted between June 2022 and April 2023 according to the experimental research model with pre-test and post-test control group. The research was completed with a total of 60 hemodialysis patients, 30 in the experimental group and 30 in the control group.


Eligibility Criteria:
Inclusion Criteria:

Being on hemodialysis treatment Being able to read and writeH

Exclusion Criteria:

Not knowing how to read or write, Having a psychological disorder that prevents speaking
Beta Blockers for the Treatment of Asthma

Current asthma medicines include inhalers. A common inhaler used in asthma is called a beta-agonist (for example salbutamol). They improve asthma symptoms by stimulating areas in the human airway resulting in widening of the human airway. Although these drugs are useful after the first dose, longterm use can cause worsening asthma symptoms.

Beta-blockers are the complete opposite type of medication. Just now they are avoided in patients with asthma as after the first dose they can cause airway narrowing and cause an asthma attack.

New research has suggested that long term use of beta-blockers can reduce airway inflammation which can improve asthma control and improve symptoms.

This research was done in asthmatic patients who didn't need inhaled steroids to control their asthma. What the investigators want to do is see if the same benefit of beta-blocker use is asthma can be seen in people who take inhaled steroids.


Eligibility Criteria:
Inclusion Criteria:

* Male and female volunteers with stable mild intermittent or mild persistent asthma.
* Stable defined as: FEV1 (Forced Expiratory Volume in 1second) \>80% predicted with diurnal FEV1 variation \<30% when LABA (Long Acting Beta Agonist) washed out.
* Methacholine PC20 \<4mg/ml.
* Ability to perform spirometry, IOS (Impulse Oscillometry), bronchial challenge and all domiciliary measurements.
* Ability to obtain Informed consent.
* Mild to Moderate Asthmatics taking ≤1000μg BDP (Beclomethasone Diproprionate) per day or equivalent.
* Withhold LABAs for 1 week prior to study.

Exclusion Criteria:

* Uncontrolled symptoms of asthma.
* Resting BP (Blood Pressure) \<110 systolic or HR (Heart Rate)\<60.
* Pregnancy or lactation.
* Known or suspected sensitivity to the IMP (Investigational Medicinal Product)(s).
* Inability to comply with protocol.
* Any degree of heart block.
* Rate limiting medication including β blockers, rate limiting Calcium - Channel Blockers and Amiodarone.
* Any other clinically significant medical condition that may either endanger the health or safety of the participant, or jeopardise the protocol.
* An asthma exacerbation within the last 6 months.
The Neuromuscular Effect of Rocuronium in Patient

Rocuronium block neuromuscular transmission at the neuromuscular junction, causing paralysis of the affected skeletal muscles. There have been several studies reported positive relationship between muscle mass and amount of neuromuscular junction. The purpose of this study is to find 50% effective dose and 95% effective dose of rocuronium according to muscle mass.

Rocuronium block neuromuscular transmission at the neuromuscular junction, causing paralysis of the affected skeletal muscles. There have been several studies reported positive relationship between muscle mass and amount of neuromuscular junction. Until now, dose of rocuronium has been judged by patient's weight and height. When the rocuronium was developed, 50% effective dose and 95% effective dose of rocuronium was calculated by patient corrected body weight which used weight and height. However, height and weight do not represent exact muscle mass. The purpose of this study is to find 50% effective dose and 95% effective dose of rocuronium according to muscle mass. Measurement of muscle mass will be obtained using bioelectrical impedence analysis.

Eligibility Criteria:
Inclusion Criteria:

* All patient who undergo general anesthesia

Exclusion Criteria:

* Liver and kidney disease
* Any types of muscle disorder.
* Metal materials or pacemaker in body
Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma

Primary liver cancer is currently the fourth most common malignant tumor and the second leading cause of tumor mortality in China, posing a serious threat to the lives and health of the Chinese people . At present, non-surgical treatment methods are often used, such as radiofrequency ablation (RFA), Transcatheter arterial chemoembolization (TACE), radiation therapy, and systemic anti-tumor therapy. However, whether it is surgical treatment or non-surgical treatment, commonly used liver cancer related biomarkers in clinical practice during the evaluation of treatment efficacy or regular follow-up of patients include AFP, AFP-L3%, DCP, etc. , but there are no reports on whether AKR1B10 can be used for the efficacy evaluation of these treatment methods.Therefore, this project aims to explore the clinical value of AKR1B10 in evaluating the efficacy of liver cancer treatment.

Patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolisation (TACE) are enrolled in this clinical trial. In the early stage, a research team detected the levels of AKR1B10 in serum samples from 477 normal individuals, 107 benign liver tumors, 32 patients with chronic hepatitis B, 78 patients with liver cirrhosis, and 482 patients with liver cancer, and evaluated its early diagnostic value in liver cancer. It was found that AKR1B10 protein, as a serum marker for liver cancer, had significantly better performance than AFP, mainly reflected in three aspects: first, it is more sensitive, The normal background level (reference range) of AKR1B10 is significantly lower than AFP, which means that during clinical testing, changes in serum concentration are more pronounced, making it easier to identify asymptomatic early liver cancer patients; Secondly, it is more specific and has a higher detection rate for liver cancer, with lower false positive and false negative rates. In addition, more than 70% of liver cancer patients who test negative for AFP will be tested positive for AKR1B10, resulting in lower rates of missed diagnosis and misdiagnosis; Thirdly, the time to reflect changes in the condition is 6-7 times faster than AFP. The half-life of AKR1B10 is 23 hours, while AFP has a half-life of 6-7 days.This project mainly aims to explore the clinical value of AKR1B10 in evaluating the efficacy of liver cancer treatment.

Eligibility Criteria:
Inclusion Criteria:

* age between 18 and 80
* diagnosis of HCC according the AASLD criteria
* TACE is planned
* resection is impossible
* No significant underlying medical illness affecting patient's survival
* Patients available for regular follow-up according to the study protocol

Exclusion Criteria:

* Previous history of other tumors;
* Combined with other tumors;
* Received external treatment before admission;
* Patients who have received blood transfusions within one month;
* The patient was unable to participate in this study for other reasons.
Mobility Training Using a Bionic Knee Orthosis in Patients Chronic Post-Stroke: A Case Series

This pilot study examined the effect of task-oriented mobility training in three persons chronic post-stroke using a novel, wearable, mobile intention-based robotic orthosis (Tibion Bionic Leg).


Eligibility Criteria:
Inclusion Criteria:

* Male or female
* Aged 40 to 60 years
* One year status post-stroke
* Able to walk at least 10 meters
* Independence in self-care

Exclusion Criteria:

* Medically unstable
* Major cardiopulmonary deficiency
* Major depression
* Significant cognitive deficit
* Currently receiving gait training
* Younger than 40 years of age
* Older than 60 years of age
* Unable to walk at least 10 meters
Effects of Sea Buckthorn Oil on Dry Eye

The objective is to study the effect of sea buckthorn oil on dry eye.

The objective is to study whether regular consumption of sea buckthorn berry oil can relieve the symptoms of dry eye syndrome. The study design is a parallel randomized double-blind placebo controlled trial. The participants daily consume sea buckthorn or placebo oil for 3 months. The dry eye symptoms will be monitored during the study using a validated questionnaire. In addition clinical dry eye tests are made by an ophthalmologist three time during the study. Samples will be taken for tear film lipid and cytokine analyses. Blood samples for the analyses of inflammatory markers are also obtained. The cytokine and other inflammation marker analyses are optional. The symptoms will be monitored and clinical tests made also 4 weeks after the participants have stopped consuming the study oils.

Eligibility Criteria:
Inclusion Criteria:

* Dry eye symptoms

Exclusion Criteria:

* Severe illness
* Anticholinergic drugs
* Smoking
Detection, Education, Research and Decolonization Without Isolation in Long-term Care Facilities

Our hypothesis for the DERAIL MRSA program is that one can safely remove the colonization risk from nearly all residents (patients) in a way that does not interfere with the desired life-style for persons in these facilities and thereby reduce the risk of infection and lower the cost of care by avoiding preventable disease.

The primary endpoint will be measuring the reduction in MRSA colonization prevalence (percentage rate) in the intervention arm as compared to the control arm. One secondary endpoint is to compare the rate of MRSA disease (number of infections per 1,000 patients and 10,000 patient days) in the intervention and control arms. The other secondary endpoint is to determine the cost of MRSA screening and decolonization and compare it to the cost of MRSA disease treatment (both medication cost and the expense of any needed hospitalization for therapy of MRSA infection therapy) in the control arm. Achieving our primary goal of MRSA control will also demonstrate two secondary goals wthe investigators aim to achieve: one being that a scientific, planned approach to the issue of specific healthcare-associated infection in LTCFs can resolve these problems and the other that a partnership between acute and long-term care (e.g., ongoing relationship spanning at least 5 years) is beneficial in dealing with patient safety and quality practices across the United Sates Healthcare continuum.

Eligibility Criteria:
Inclusion Criteria:

* All patients in 18 LTCF nursing units randomly selected as intervention or control units

Exclusion Criteria:

* Patients that choose not to be included in the program
Incidence of Sub-clinical Cystoid Macular Edema After Cataract Surgery

Cystoid macular edema (CME) can limit visual acuity after cataract surgery. Little is known whether the incidence is similar between standard ultrasound phacoemulsification cataract surgery (phaco), femtolaser assisted cataract surgery (FLACS), and combined phacoemulsification cataract surgery plus micro invasive glaucoma surgery (phaco+MIGS) procedures.

Subclinical cystoid macular edema (CME) can limit visual acuity after cataract surgery. Little is known whether the incidence is similar between standard ultrasound phacoemulsification cataract surgery (phaco), femtolaser assisted cataract surgery (FLACS), and combined phacoemulsification cataract surgery plus micro invasive glaucoma surgery (phaco+MIGS) procedures.

The investigators hypothesize that CME incidence will be in the following order: FLACS \< phaco \< phaco+MIGS due to the increase of inflammation with the different surgical procedures.

The study is designed as a single centre, prospective study. The study includes patients with a diagnosis of cataract or cataract and glaucoma who will undergo one of the three above mentioned sürgical procedures at the Department of Ophthalmology at the UniversityHospital Zurich (USZ), Zurich, Switzerland. CME will be assessed by optical coherence tomography of the macular with Heidelberg Spectralis SD-OCT of the Macular at: baseline (i.e. preoperative), 1 week, 1 month, 3 months, and 6 months post-surgery. Furthermore, a swept source Optical Coherence Tomography Angiography (OCT-A) using Zeiss Plex Elite 9000 will be performed at: baseline (i.e. preoperative), 1 week, 1 month, and 6 months post-surgery to image the retinal vessels.

Eligibility Criteria:
Inclusion Criteria:

* Patients with a diagnosis of cataract or
* Patients with a diagnosis of cataract and open angle glaucoma
* Signed lnformed Consent
* Patients at the age of 18 or older

Exclusion Criteria:

* Loss of follow up, i.e. not available during the post-operation follow-up inteval.
* Previous known of CME, macular pathology (e.g., Diabetes, exudative age-related macular degeneration, status post retinal vein occlusion) or posterior uveitis.
* Patient unable to understand the study due to cognitive or linguistic incapacity.